Actual treatment options for locally advanced and metastatic cutaneous squamous cell carcinoma

Squamous cell carcinoma of the skin, or cutaneous squamous cell carcinoma (CSCC), is the second most frequent type of skin cancer, and its incidence continues to rise all over the world. Usually has a benign clinical behavior, but it can be presented as locally invasive and metastatic aggressive tum...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Anastasia V. Ignatova
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	non-melanoma skin cancer cutaneous squamous cell carcinoma targeted therapy epidermal growth factor receptor braf inhibitors immunosuppression immunotherapy immune checkpoint inhibitors cemiplimab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/17d0917ea6024ef9822b5c7c90ecc84b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:17d0917ea6024ef9822b5c7c90ecc84b
record_format	dspace
spelling	oai:doaj.org-article:17d0917ea6024ef9822b5c7c90ecc84b2021-11-30T16:55:00ZActual treatment options for locally advanced and metastatic cutaneous squamous cell carcinoma1815-14341815-144210.26442/18151434.2021.1.200694https://doaj.org/article/17d0917ea6024ef9822b5c7c90ecc84b2021-05-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/70339/51273https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Squamous cell carcinoma of the skin, or cutaneous squamous cell carcinoma (CSCC), is the second most frequent type of skin cancer, and its incidence continues to rise all over the world. Usually has a benign clinical behavior, but it can be presented as locally invasive and metastatic aggressive tumor with 2% mortality rate. Nowadays, new risk factors for have appeared, that form pharmacologically-induced CSCC after immunosuppressant drugs used for organ transplantation, or BRAF inhibitors used for melanoma. In recent years we have got a new information about the role of mutational burden, signaling pathways involved in CSCC development and new possibilities and molecules for targeted therapy. Better understanding of the immune system functioning and benefits of immunotherapy with immune checkpoint inhibitors (PD-1) for CSCC that has changed the therapeutic approach. According to recent clinical trials data, new treatment options with PD-1 inhibitors achieved a response rate of 50% for locally advanced CSCC and 47% for metastatic CSCC, including 16.1% complete remissions. This review focuses on the molecular profile, targeted therapies and immunotherapy for locally advanced and metastatic CSCC.Anastasia V. IgnatovaIP Habib O.N.articlenon-melanoma skin cancercutaneous squamous cell carcinomatargeted therapyepidermal growth factor receptorbraf inhibitorsimmunosuppressionimmunotherapyimmune checkpoint inhibitorscemiplimabNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 1, Pp 94-98 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	non-melanoma skin cancer cutaneous squamous cell carcinoma targeted therapy epidermal growth factor receptor braf inhibitors immunosuppression immunotherapy immune checkpoint inhibitors cemiplimab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	non-melanoma skin cancer cutaneous squamous cell carcinoma targeted therapy epidermal growth factor receptor braf inhibitors immunosuppression immunotherapy immune checkpoint inhibitors cemiplimab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Anastasia V. Ignatova Actual treatment options for locally advanced and metastatic cutaneous squamous cell carcinoma
description	Squamous cell carcinoma of the skin, or cutaneous squamous cell carcinoma (CSCC), is the second most frequent type of skin cancer, and its incidence continues to rise all over the world. Usually has a benign clinical behavior, but it can be presented as locally invasive and metastatic aggressive tumor with 2% mortality rate. Nowadays, new risk factors for have appeared, that form pharmacologically-induced CSCC after immunosuppressant drugs used for organ transplantation, or BRAF inhibitors used for melanoma. In recent years we have got a new information about the role of mutational burden, signaling pathways involved in CSCC development and new possibilities and molecules for targeted therapy. Better understanding of the immune system functioning and benefits of immunotherapy with immune checkpoint inhibitors (PD-1) for CSCC that has changed the therapeutic approach. According to recent clinical trials data, new treatment options with PD-1 inhibitors achieved a response rate of 50% for locally advanced CSCC and 47% for metastatic CSCC, including 16.1% complete remissions. This review focuses on the molecular profile, targeted therapies and immunotherapy for locally advanced and metastatic CSCC.
format	article
author	Anastasia V. Ignatova
author_facet	Anastasia V. Ignatova
author_sort	Anastasia V. Ignatova
title	Actual treatment options for locally advanced and metastatic cutaneous squamous cell carcinoma
title_short	Actual treatment options for locally advanced and metastatic cutaneous squamous cell carcinoma
title_full	Actual treatment options for locally advanced and metastatic cutaneous squamous cell carcinoma
title_fullStr	Actual treatment options for locally advanced and metastatic cutaneous squamous cell carcinoma
title_full_unstemmed	Actual treatment options for locally advanced and metastatic cutaneous squamous cell carcinoma
title_sort	actual treatment options for locally advanced and metastatic cutaneous squamous cell carcinoma
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/17d0917ea6024ef9822b5c7c90ecc84b
work_keys_str_mv	AT anastasiavignatova actualtreatmentoptionsforlocallyadvancedandmetastaticcutaneoussquamouscellcarcinoma
_version_	1718406429309665280

Actual treatment options for locally advanced and metastatic cutaneous squamous cell carcinoma

Ejemplares similares